CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) Meeting Abstract
| Authors: | Motzer, R. J.; Sharma, P.; McDermott, D. F.; George, S.; Hammers, H. J.; Srinivas, S.; Tykodi, S. S.; Sosman, J. A.; Procopio, G.; Plimack, E. R.; Castellano, D. E.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T. C.; Ueda, T.; Zhao, H. Y.; Waxman, I. M.; Escudier, B. |
| Abstract Title: | CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) |
| Meeting Title: | 2016 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 2 Suppl. |
| Meeting Dates: | 2016 Jan 7-9 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-01-10 |
| Language: | English |
| ACCESSION: | WOS:000378109100491 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2016.34.2_suppl.498 |
| Notes: | Meeting Abstract: 498 -- Source: Wos |
